Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
October 1, 2025Head & Neck

Safety and Efficacy of Vismodegib and Sonidegib in Advanced Basal Cell Carcinoma of the Head and Neck: A Systematic Review and Meta‐Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

CDC. T. DoyleJCJevan CevikARAnand Ramakrishnan

Discussion

Loading...

Member takes

Overview

Systematic review evaluates efficacy of vismodegib and sonidegib in patients with advanced BCC, indicating significant response rates.

Key Points

  • Seventeen studies analyzed show pooled overall response rate of 84.2% for vismodegib and sonidegib in advanced BCC patients.
  • Primary outcomes include a complete response rate of 33.8% and partial response rate of 47.7% in the head and neck population.
  • Adverse effects were common, with muscle spasms, dysgeusia, and fatigue reported, leading to a 13.2% treatment discontinuation rate.
  • High efficacy suggests these targeted therapies may be viable alternatives to surgery for managing advanced BCC cases.

Cite This Study

Doyle et al. (2025) studied this question.

synapsesocial.com/papers/68dd89defe798ba2fc497d5dhttps://doi.org/10.1002/hed.70056
View Full Paper
Ask AI
Bookmark
Share